Regeneron (REGN) Tops Q4 EPS by $1.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
February 5, 2021 6:30 AM ESTTARRYTOWN, N.Y., Feb. 5, 2021 /PRNewswire/ --
Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019(4) Fourth quarter 2020 EYLEA® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019 Fourth quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, increased 56% to $1.17 billion versus fourth quarter 2019 and full year 2020 Dupixent global net sales increased 75% versus 2019 Fourth quarter 2020 GAAP diluted EPS was $10.24 and non-GAAP diluted EPS(1) was $9.53 REGEN-COV... More
